ArticleToxics2022
Fenugreek Seed Galactomannan Aqueous and Extract Protects against Diabetic Nephropathy and Liver Damage by Targeting NF-κB and Keap1/Nrf2 Axis.
Article in Toxics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Ameliorative Role of fenugreek Oil Against Lead Acetate Trihydrate-Induced Hepatic, Renal and Testicular Injury in Wistar Albino Rats: Insights into Bcl-2 Expression and sodium/potassium balance.Biological trace element research · 2026Article
- Polysaccharide fromMetabolites · 2026Article
- Compound Enzyme-Assisted Extraction and Characterization of Trigonella foenum-graecum L. Polysaccharides and Their Ameliorative Effects on MAFLD.Chemistry & biodiversity · 2026Article
- Effects of dietary supplementation with fenugreek oil on growth, physiology, and resistance toOpen veterinary journal · 2025Article
- Role of aqueous fenugreek (Trigonella foenum-graecum) extract against DBP-induced renal and adrenal pathologies in male rats.Journal of molecular histology · 2025Article
- Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents.Archives of pharmacal research · 2025Review
- Solid-State Fermented Cereals: Increased Phenolics and Their Role in Attenuating Liver Diseases.Nutrients · 2025Review
- A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy.Current molecular medicine · 2025Review
- Metabolic profiling and antioxidant activity of fenugreek seeds cultivars 'Giza 2' and 'Giza 30' compared to other geographically-related seeds.Food chemistry: X · 2024Article
- The Role of Fenugreek in the Management of Type 2 Diabetes.International journal of molecular sciences · 2024Review
- Review
- Evaluation of the antihyperglycemic and antihyperlipidemic effects ofThe Pan African medical journal · 2024Article
- NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials.Frontiers in medicine · 2023Review
- Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols.Frontiers in immunology · 2023Review
- Sclareol ameliorates liver injury by inhibiting nuclear factor-kappa B/NOD-like receptor protein 3-mediated inflammation and lipid metabolism disorder in diabetic mice.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
This investigation was conducted to test the potential of the galactomannan (F-GAL) and aqueous extract (FS-AE) of the Fenugreek seed aqueous to prevent liver and kidney damage extracts in streptozotocin (STZ)-induced T1DM in rats. Non-diabetic and diabetic rats received the normal saline as a vehicle or were treated with FS-EA or F-GAL at a final concentration of 500 mg/kg/each. Treatments with both drugs reduced fasting hyperglycemia and improved serum and hepatic lipid profiles in the control and diabetic rats. Additionally, F-GAL and FS-AE attenuated the associated reduction in the mass and structure of the islets of Langerhans in diabetic rats and improved the structure of the kidneys and livers. In association, they also reduced the generation of reactive oxygen species (ROS), lipid peroxides, factor (TNF-α), interleukin-6 (IL-6), and nuclear levels of NF-κB p65, and improved serum levels of ALT, AST, albumin, and creatinine. However, both treatments increased hepatic and renal superoxide dismutase (SOD) in the livers and kidneys of both the control and diabetic-treated rats, which coincided with a significant increase in transcription, translation, and nuclear localization of Nrf2. In conclusion, FS-AE and F-GAL are effective therapeutic options that may afford a possible treatment for T1DM by attenuating pancreatic damage, hyperglycemia, hyperlipidemia, and hepatic and renal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.